natgillin/translations-raw huggingface dataset:
The system of claim 9, wherein the system is configured to combine the pulses provided by the first pump segment and the second pump segment to form a resultant flow that has pulsation amplitudes that are smaller than pulsation amplitudes of the pulses provided by the first pump segment and smaller than pulsation amplitudes of the pulses provided by the second pump segment. 
Sustav prema zahtjevu 7, naznačen time, da je sustav uređen tako da kombinira pulseve (601a, 601b) dobivene od prvog segmenta (1034) sisaljke 1 drugog segmenta (103b) sisaljke za tvorbu rezultante protoka, čije su pulsacijske amplitude manje nego pulsacijske amplitude pulseva dobivenih od prvog segmenta sisaljke i manje nego pulsacijske amplitude pulseva dobivenih od drugog segmenta sisaljke.
Use of a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof, in combination with a calcium antagonist, for manufacture of an agent for the prophylaxis or treatment of diseases in which insulin resistance is involved. 
2 07-o-R N-Q ko JA gdje R! je kao definiran u zahtjevu 1, ili njegova sol, u kombinaciji s antagonistom kalcija, za proizvodnju sredstva za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
According to a still further aspect of the present invention there is provided for a process for the preparation of the nearly spherical pellets containing the pharmaceutical ingredient venlafaxine, which comprises admixing at most 80% of the active ingredient with 10 to 60% by weight of microcrystalline cellulose, 10 to 60% by weight of sodium chloride and/or potassium chloride and optionally other, pharmaceutically acceptable excipients and/or additives promoting the pelletization, converting the thus-obtained mixture into pellets by high-shear mixing, rotofluidization or extrusion-spheroidization method, preferably by rotofluidization by spraying water or preferably an aqueous dimethyl polysiloxane emulsion and/or an aqueous solution of xanthane gum, drying the pellets, separating the desired product fraction and optionally coating the pellets with a layer to modify the drug release. 
Sukladno sljedećem aspektu ovog izuma definiran je postupak priređivanja gotovo kuglastih granula koje sadrže farmaceutski sastojak venlafaksin, Å to obuhvaća miješanjem najviše 80% aktivnog sastojka s 10 do 60% (težinski) mikrokristalne celuloze, 10 do 60% (težinski) natrijeva klorida i/ili kalijeva klorida i proizvoljno drugih farmaceutski prihvatljivih ekscipijenata i/ili dodataka koju pomažu granuliranje, te se tako dobivena smjesa prevodi u granule pomoću 'high-shear' miješanja, rotacijskih fluidiziranjem ili metodom ekstruzije-sferoidizacije, poželjno rotacijskim fluidiziranjem raspršivanjem vode ili poželjno vodene emulzije dimetil polisiloksana i/ili vodene otopine ksantanske gume, sušenjem granula, odvajanjem željene frakcije produkta i proizvoljno prevlačenjem granula određenim slojem da bi se promijenilo otpuštanje lijeka.
It is contemplated that hydroxyl groups of rapamycin or a rapamycin metabolite, including those that are located in positions other than 31- and 42-, can also be glycosylated as described herein, and the resultant rapamycin carbohydrate derivatives will also exhibit higher water-solubility and/or enhanced pharmacokinetic and/or pharmacodynamic properties compared to their unglycosylated counterparts. 
Smatra se da hidroksilne grupe rapamicina ili rapamicinskog metabolita, uključujući i one smještene na položajima koji nisu 31- ili 42-, također mogu biti glikozilirane ovdje opisanim postupkom, a nastali ugljikohidratni derivati rapamicina također će pokazivati bolju topljivost u vodi i/ili poboljšana farmakokinetička i/ili farmakodinamička svojstva, u usporedbi sa svojim neglikoziliranim parom.
The mixture was stirred at 20°C under nitrogen atmosphere for 12h. 
Smjesu se miješa 12 sati na 20 *C u atmosferi dušika.
discharge of the emulsion of fluid components (i.e. oils/liquids) from the washing chamber 101 through the outlet 103 of the washing and separating container 1 (FIG. 
pražnjenja emulzije od tekućih komponenti iz komore (101) za ispiranje kroz odvod (103) spremnika (1) za ispiranje i odvajanje; -
Crude asenapine maleate monoclinic form (20 kg) was dissolved in acetone (87.6 kg) and heated to 55°C. The solution was passed through a filter to remove undissolved materials. 
Kruti asenapin maleat monoklinskog oblika (20 kg) otopljen je u acetonu (87,6 kg) i zagrijavan na 55 *C. Otopina je provedena preko filtra da bi se uklonio neotopljeni materijal.
A therapeutic and/or prophylactic agent for a tumor used for a patient with a mutation in RET and for metastasis of the tumor, which comprises a compound represented by formula (I), a salt thereof or a solvate thereof as an active ingredient: wherein R1 is a C1-6 alkyl group. 
Terapijsko i/ili profilaktičko sredstvo namijenjeno upotrebi u liječenju tumora koje se upotrebljava kod pacijenta s mutacijom u RET-u i namijenjeno upotrebi u liječenju metastaze tumora, naznačeno time što sadrži spoj prikazan formulom (I), njegovu sol ili njegov solvat, kao aktivni sastojak: gdje je Ri C14 alkilna skupina.
The extracts were dried (MgSO4), filtered, concentrated and dried in vacuum to give intermediate 37 (1.3 g, 76%) as a solid. 
Ekstrakti su sušeni (MgSO,), filtrirani, koncentrirani 1 sušeni u vakuumu Intermedijer 37 HR P20080531 T3 da bi se dobio Intermedijer 37 (1.3g, 76%) kao čvrsta supstanca.
The fusion may be direct, or via a short linker peptide which can be as short as 1 to 3 amino acid residues in length or longer, for example, 13 amino acid residues in length. 
Fuzija može biti izravna ili preko kraćeg veznog peptida koji može biti kratak od 1 do 3 aminokiseline ili dulji, na primjer 13 aminokiselina.
Solar concentrator according to Claim 1, characterized in that the nanocrystals (2) comprise alloys of said at least ternary semiconductors. 
Koncentrator sunčevog zračenja u skladu s patentnim zahtjevom 1, naznačen time što nanokristali (2) sadrže legure navedenih u najmanju ruku ternarnih poluvodiča.
Where technical features mentioned in any claim are followed by reference signs, those reference signs have been included for the sole purpose of increasing the intelligibility of the claims and accordingly such reference signs do not have any limiting effect on the interpretation of each element identified by way of example by such reference signs. 
Kada su tehničke značajke navedene u patentnim zahtjevima popraćene referentnim znakovima, isključiva je svrha takvih referenci povećati razumljivosti patentnih zahtjeva, stoga takve reference nikako ne ograničavaju tumačenje elemenata koji su na takav način određeni. HR P20080256 T3 PATENTNI ZAHTJEVI
The invention further provides a method of making an antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, comprising 
Protutijelu sličan vezivni protein koji sadrži četiri polipeptidna lanca koji tvore četiri mjesta vezanja antigena, pri čemu dva polipeptidna lanca imaju strukturu predstavljenu s formulom:
Pharmaceutical formulation which comprises a pharmaceutical form as defined in anyone of claims 1 to 9 wherein, said pharmaceutical formulation presents a humidity percentage (w/w) lower than 10%. Pharmaceutical formulation according to claim 10, wherein the compound presenting quaternary ammonium groups form part of the surface of the said formulation. 
Farmaceutska formulacija koja se sastoji od farmaceutskog oblika definiranog u patentnom zahtjevu 9 naznačena time se komponenta prikazuje kao skupine kvaternog amonijaka koje čine dio površine navedene formulacije.
Therefore, n and/or m are preferably 1 and X1 and/or X7 are preferably cysteine (C). 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, dan i/ili m su 1, a X, i/ili X; su cistein (C).
A preferred embodiment of the invention is that the reaction is carried out with a base such as potassium t-butoxide in the presence of an isopropanol/THF mixture. 
Postupak prema zahtjevu 1 gdje se pretvorba provodi reakcijom spoja formule IV s dimetillsulfoksonij metilidom da se dobije odgovarajući keto sulfoksonij ilid formule
The compound, the pharmaceutically acceptable salt, or the solvate thereof, for use in treating and/or preventing influenza infectious disease according to any one of claims 1 to 5, wherein R2 is hydrogen, lower alkyl optionally substituted by substituent group A, carbocycle lower alkyl optionally substituted by substituent group A, heterocycle lower alkyl optionally substituted by substituent group A, or -Z-N(RY9)(RY10) (Substituent group A, RY9, RY10, and Z are same meaning as those of claim 1). 
Spoj, njegova farmaceutski prihvatljiva sol, ili njegov solvat, za uporabu u liječenju i/ili prevenciji infektivne bolesti gripe prema bilo kojem od zahtjeva 1 do 5, naznačen time, da R? je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom A,ili Z-NRKAR'), (Supstituentska skupina A, R, 1Z, imaju isto značenje kao što su navedeni u zahtjevu 1).
In order to produce a conductive flooring the following materials were used: Conductive silver glass spheres (CSGS 10 A,available from Progessive Fillers Int'I Inc. of Tennessee, USA) having a mean particle size of 10 µm, a pure silver plating of 12% and a dry bulk resisitivty of 0.001 Ohms/cm 
Za proizvodnju vodljive podne obloge korišteni su sljedeći materijali: 1) Vodljive posrebrene staklene kuglice (CSGS 10 A, dostupne od tvrtke Progessive Fillers Int'I Inc. Tennessee, SAD) srednje veličine čestica od 10 um, 12%-tni premaz od čistog srebra s električnim otporom u suhom nasipnom volumenu veličine 0,001 Ohm-cm.
The method according to claim 8, wherein the acid addition salt of amino-guanidine or 1,3-diaminoguanidine is heated together with the at least one diamine, initially to a first, lower temperature and then to a second, higher temperature. 
Postupak u skladu s patentnim zahtjevom 8 ili 9, naznačen time, da se sol aminogvanidina ili 1,3-diaminogvanidina zagrijava zajedno s navedenim najmanje jednim diaminom, najprije na prvu nižu temperaturu, a zatim na drugu višu temperaturu.
Useful light chain constant regions include any of the two isotypes: k and λ. 
SEK.: 143 i sekvencu varijabilne regije lakog lanca ID BR.
The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I), R5 is a phenyl group, a thienyl group, a naphthyl group, a dihydrobenzofuranyl group, a benzodioxolyl group, a benzothiadiazolyl group, a benzothienyl group or a quinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group F [wherein the group F consists of a C1-C6 alkyl group, a halogen atom, a trifluoromethyl group, a C1-C6 alkoxy group, a nitro group, a cyano group, and a C2-C7 alkanoyl group], or a C2-C8 alkenyl group which may be substituted with a phenyl group(s). 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da u formuli (1), R> je fenilna skupina, tienil skupina, naftil skupina, dihidrobenzofuranil skupina, benzodioksolil skupina, benzotiadiazolil skupina, benzotienil skupina ili kinolinil skupina, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta odabrana iz skupine F [pri čemu skupina F sadrži C;-Cg alkilnu skupinu, atom halogena, trifluorometilnu skupinu, C,-CÂ« alkoksi skupinu, nitro skupinu, cijano skupinu, te C»-C; alkanoil skupinu], ili C>-Cg alkenil skupinu koja može biti supstituirana sa fenil skupinom(ama).
Wheat hydrolysate at a concentration ranging from about 8000 to about 12000 mg/L, most preferably about 10000 mg/L. 
-Hidrolizat pšenice u koncentraciji u rasponu od oko 8000 do oko 12000 mg/L, najpoželjnije oko 10000 mg/L.
A process for preparing the compound of claim 1, comprising: Mitsunobu coupling or transesterification of compound (1) and compound (4) and deprotecting the product to form compound (5): 
(a) sprezanje spoja (1) i spoja (2) u uvjetima za nastanak amidne voze te skidanje zaštite, čime se dobiva spoj (3): m").
The use of preservatives and masking agents is suitable. In yet another aspect of the invention is a method of treatment of inflamatory diseases, disorders, and conditions characterized by or associated with an undesirable inflammatory immune response and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1 which comprises administering to a subject a therapeutically effective amount of a compound of the invention. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s nepoželjnim upalnim imunosnim odgovorom, te svim bolestima i stanjima uzrokovanim ili povezanim s prekomjernim izlučivanjem TNF-a i IL-1.
any amino acid of said peptide may be independently either in the L-configuration or D-configuration; wherein if the peptide derivative comprises a cysteine, said peptide derivative is optionally a dimer. 
bilo koja aminokiselina navedenog peptida može biti neovisno ili u L-konfiguraciji ili u D-konfiguraciji; pri čemu ako peptidni derivat sadrži cistein, navedeni peptidni derivat je po izboru dimer.
A method of treating a subject with an infectious disease, or at risk of becoming infected with an infectious disease, or with cancer, or at risk of developing cancer, comprising selecting a subject in need of treatment and administering to the subject the recombinant RhCMV or HCMV vector of any one of items 1-20, or the composition of item 21. 
Rekombinantni vektor RRCMYV ili HCMV u skladu s bilo kojim od patentnih zahtjeva 1-11, ili pripravak u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u postupku liječenja subjekta sa zaraznom bolešću, ili je u opasnosti od zaražavanja zaraznom bolešću, ili s rakom, ili je u opasnosti od razvoja raka.
The present invention is based on reactive diluents that do not suffer from this drawback. 
Predloženi izum se temelji na reaktivnim sredstvima za razrjeđivanje koja ne pate od tog nedostatka.
Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; 
Spoj patentnog zahtjeva 1 izabrano iz grupe koja se sastoji od: ord ' no:
The pharmaceutical composition of any one of claims 8 to 12, wherein said pharmaceutical composition is a vaccine. 
Farmaceutski pripravak sukladno bilo kojem patentnom od zahtjeva 8 do 12, naznačen time što je navedeni farmaceutski sastav cjepivo.
Within the extrusion ridge oriented towards the outside of the box a storage space is formed, useful for placement of a lighter or other objects within. 
Unutar prijeloma u obliku izbočenja usmjerenog prema vanjskom dijelu kutije nalazi se spremišni prostor, pogodan za držanje upaljača ili drugih predmeta.
An anti-IL-6 antibody for use as a diagnostic agent according to claim 9, wherein the use is for diagnostic in vivo imaging wherein the use 
Protutijelo ili fragment protutijela za uporabu kao dijagnostički agens u skladu s patentnim zahtjevom 9, pri čemu je uporaba za dijagnostičke in vivo slikovne tehnike gdje je uporaba
A method according to claim 9, wherein the method is performed for a duration of at least 8 weeks. 
Uporaba polietilen glikola prema zahtjevu 17, naznačena time, da je razdoblje primjene najmanje 8 tjedana.
A xylenes (200 ml) solution of crude intermediate 8 (100 mmol) was heated at reflux for 24 h, cooled and concentrated. 
Otopina u ksilenima (200 ml) sirovog Intermedijera 8 (100 mmol) zagrijavana je na refluksu 24 sata, hlađena 1 koncentrirana.
Vessel according to any of claims 13-16, comprising a system according to any of clams 1-9, the vessel accommodating for each cavity or pair of cavities on opposite sides of the center line at a predetermined length position, a corresponding compressor (11,12) for injecting air into the cavity at a pressure substantially corresponding to the hydrostatic pressure in each cavity. 
Plovilo u skladu s bilo kojim od patentnih zahtjeva 1-4, kod kojeg za svaki par šupljina na suprotnim stranama središnje linije smještenih u unaprijed određenom položaju, postoji odgovarajući kompresor (11, 12) za ubrizgavanje zraka u par šupljina pod visokim tlakom koji odgovara hidrostatskom tlaku u svakoj šupljini.
The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 27 and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 31. The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the isolated antibody or antigen binding fragment thereof is a Fv, a scFv, a Fab or a F(ab′)2. The pharmaceutical composition of claim 13, further comprising a second therapeutic agent. 
Humanizirano protutijelo ili njegov za antigen vezni fragment prema zahtjevu 1, koji se za vezanje za LOXL2 natječu s protutijelom ili njegovim za antigen veznim fragmentom koji obuhvaćaju varijabilni teški lanac s aminokiselinskom sekvencom prema SEQ ID NO:1 i varijabilni laki lanac s aminokiselinskom sekvencom prema SEQ ID NO:2. Protutijelo ili njegov za antigen vezni fragment prema bilo kojem od zahtjeva 1-10, gdje je protutijelo ili fragment obilježeno terapijskom oznakom ili dijagnostičkom oznakom.
The method according to claim 17, wherein said flat surface or shape is made of rigid materials which are resistant to temperature and pressure, said shape having small cavities which are complementary, at overlaps of the elements, with respect to the differences in thicknesses or the stitched seams of the semimanufactured component of the upper, so that an inner surface of the semimanufactured component of the upper and a pressing surface of the membrane, is flat. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time, da kada su navedena ravna površina ili oblik (20) izrađeni od krutih materijala koji su otporni na temperaturu i tlak, navedeni oblik ima male šupljine (20a), koje su komplementarne, na preklapanjima elemenata s obzirom na razlike u debljini ili šivane šavove gornjišta (12) tako da je unutarnja površina gornjišta (12), to jest površina membrane za prešanje, ravna.
The cellulose reactive glyoxalated copolymer composition according to claim 1, wherein the cationic copolymer comprises about 20 to about 40 weight % diallyldimethylammonium halide monomer and about 80 to about 60 weight % acrylamide monomer, and has a weight average molecular weight of about 150,000 to about 400,000 Daltons. 
Sastav glioksaliranog kopolimera reaktivnog sa celulozom prema bilo kojem od zahtjeva 1-5, gdje kationski kopolimer sadrži 20 do 40 masena % dialildimetilamonij halid monomera i 80 do 60 masena % akrilamid monomera, te ima maseni prosjek molekulske mase od 150,000 do 400,000 Daltona.
The mono-lysine salt or solvate thereof according to claim 1, wherein A is selected from the group consisting of and 
Mono-lizinska sol ili njezin solvat prema zahtjevu 1, naznačena time, da je A odabran iz skupine koja sadrži [image] [image] i [image]
A first nucleic acid molecule encoding a 1st human IgG CH3 domain-comprising polypeptide chain comprising a lysine (K) residue at amino acid position 366 according to the EU numbering system, 
prve molekule nukleinske kiseline koja kodira prvi polipeptidni lanac koji sadrži CH3 domenu humanog IgG koji sadrži lizin (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavu numeracije, b.
The peptide of item 2 or 3, wherein the C-terminal amino acid is phenylalanine, leucine, isoleucine, tryptophan, or methionine. An isolated peptide of less than about 15 amino acids selected from the group consisting of peptides comprising the amino acid sequences of SEQ ID NO: 376, 379, 114, 116, 117, 121, 227, 228, 233, 254, 271, 272 or 288. A peptide having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: SEQ ID NO: 376, 379, 114, 116, 117, 121, 227, 228, 233, 254, 271, 272 or 288, wherein 1, 2, or several amino acids are substituted, deleted, or added. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78, u kojima je jedna aminokiselina zamijenjena, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4. Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed u kojem je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, tirozinom, metioninom ili triptofanom i/ili je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, leucinom, izoleucinom, triptofanom ili metioninom, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
obtaining (S1909) the PLP identified by the PLP identifier in the layer-1 information and the data slice identified by the data slice identifier in the layer-1 information, wherein the PLP is mapped to a transport stream using the PLP identifier, the identifier of the transmission system, the information for a tuning frequency of the transmission system, the active OFDM symbol duration field and the guard interval field in the descriptor in the NIT; and obtaining (S1911) the transport stream from the obtained PLP. 
dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru C2 sustava uključenog u NIT; i dobivanje prijenosnog toka (transport stream, TS) prema kojem je PLP mapiran, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a i identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava. Postupak prema zahtjevu 1, gdje NIT obuhvaća identifikator prijenosnog toka i identifikator mreže.
The compound of clause 28, wherein R7 is -CH3. The compound of clause 1, wherein the compound is selected from the compounds delineated in Table 1. 
Spoj prema zahtjevu 1, pri čemu je spoj odabran od skupine koja se sastoji od ili njegova farmaceutski prihvatljiva sol, stereoizomer, 1/ili N-oksid.
The device of claim 4, wherein the first linear actuator and the second linear actuator are double-acting pneumatic cylinders. 
Uređaj sukladno zahtjevu 5 ili zahtjevu 6, pri čemu su prvi linearni pokretač (68, 70) i drugi linearni pokretač (74, 76) dvostruko djelujući pneumatski cilindri.
The immunogenic composition of clause 38, wherein said composition comprises at least 2 µg PCV2 ORF2 protein. A container comprising at least one dose of the immunogenic composition of clause 38, wherein one dose comprises at least 2 µg PCV2 ORF2 protein. 
Garnitura, naznačena time, da obuhvaća najmanje jedan spremnik u kojem je najmanje jedna doza sastava prema zahtjevu 29, pri čemu je navedeni sastav imunogeni sastav, a jedna doza sadrži najmanje 2 ug PCV2 proteina otvorenog okvira 2 za čitanje.
Device according to claim 4, characterized in that the rotational movement is a movement of at least 30° on either side of the centre line (31). 
Uređaj sukladno zahtjevu 4, naznačen time, što rotacijsko pomeranje predstavlja pomjeranje od najmanje 30% na obje strane od središnje linije (31).
There is no particular restriction on the nature of the base to be used in this reaction, and any base conventionally used in reactions of this type may equally be used here, provided that it has no adverse effect on other parts of the molecule. 
Nema nikakvog posebnog ograničenja u prirodi baze koju bi se upotrijebilo u ovoj reakciji, te se bilo koju bazu koju se obično upotrebljava u reakcijama ovog tipa može isto tako upotrijebiti i ovdje, uz uvjet da to ne utječe štetno učinaka na druge dijelove molekule.
The present invention concerns novel compounds of Formula (RI), 
HR P20171351 T1 PATENTNI ZAHTJEVI Spoj prema formuli (RI),